Loading...
XNASGTBP
Market cap6mUSD
Dec 26, Last price  
3.09USD
1D
-3.44%
1Q
45.75%
IPO
-99.89%
Name

GT Biopharma Inc

Chart & Performance

D1W1MN
XNAS:GTBP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-14.53%
Rev. gr., 5y
%
Revenues
0k
2,364,0002,497,0005,776,0006,049,0001,143,00048,00011,00026,000342,000368,00061,00027,00000000000
Net income
-8m
L-62.95%
-2,656,000-3,109,000-4,940,000471,000-5,006,000-2,246,000-2,995,000-3,700,000-5,171,000-501,000-23,489,000-32,726,00021,033,000-143,247,000-259,186,000-40,775,000-31,616,000-58,693,000-20,503,000-7,597,000
CFO
-9m
L-41.83%
-3,292,000-2,093,000-671,000-270,000-169,000-937,000-1,535,000-963,000-987,000-442,000-1,749,000-4,657,000-1,930,000-5,430,000-10,677,000-3,659,000-7,262,000-15,606,000-15,217,000-8,852,000
Earnings
Mar 24, 2025

Profile

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
URL
https://www.gtbiopharma.com/
IPO date
Oct 22, 2013
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
6,466
8,811
57,515
Unusual Expense (Income)
NOPBT
(6,466)
(8,811)
(57,515)
NOPBT Margin
Operating Taxes
(381)
680
Tax Rate
NOPAT
(6,466)
(8,430)
(58,195)
Net income
(7,597)
-62.95%
(20,503)
-65.07%
(58,693)
85.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,268
(189)
41,112
BB yield
-60.80%
0.67%
-47.87%
Debt
Debt current
116
110
31
Long-term debt
58
238
Deferred revenue
Other long-term liabilities
Net debt
(13,798)
(16,160)
(31,948)
Cash flow
Cash from operating activities
(8,852)
(15,217)
(15,606)
CAPEX
Cash from investing activities
(2,009)
12,145
(23,040)
Cash from financing activities
6,268
(224)
42,317
FCF
(6,354)
(8,595)
(61,294)
Balance
Cash
13,972
16,508
31,979
Long term investments
Excess cash
13,972
16,508
31,979
Stockholders' equity
(682,063)
(674,434)
(651,325)
Invested Capital
689,655
686,342
673,266
ROIC
ROCE
EV
Common stock shares outstanding
1,348
1,062
939
Price
7.65
-71.21%
26.57
-70.96%
91.50
-57.69%
Market cap
10,310
-63.47%
28,225
-67.13%
85,875
171.68%
EV
(3,487)
12,066
53,928
EBITDA
(6,466)
(8,811)
(57,515)
EV/EBITDA
0.54
Interest
8
718
Interest/NOPBT